Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 20/20 | 0.61 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16302833 | 0.82 | GRIN2B (0.53) | GRIN2BGRIN1 | |
| SCHEMBL16302842 | 0.81 | GRIN2B (0.59) | GRIN2BGRIN1 | |
| SCHEMBL16302761 | 0.78 | GRIN2B (0.50) | GRIN2BGRIN1 | |
| SCHEMBL18363574 | 0.76 | GRIN2B (1.00) | GRIN2BGRIN1 | |
| SCHEMBL17754800 | 0.72 | GRIN2B (0.60) | GRIN2BGRIN1 | |
| SCHEMBL18363360 | 0.72 | GRIN2B (1.00) | GRIN2B | |
| SCHEMBL18363215 | 0.71 | GRIN2B (1.00) | GRIN2B | |
| SCHEMBL18363491 | 0.71 | GRIN2B (1.00) | GRIN2B | |
| SCHEMBL18363310 | 0.71 | GRIN2B (1.00) | GRIN2BGRIN1 | |
| SCHEMBL7975279 | 0.70 | RPS6KA5 (0.40) | GRIN2BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912330-B2 | Azaindole derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20110294806-A1 | AZAINDOLE DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294806-A1 | AZAINDOLE DERIVATIVES AS KINASE INHIBITORS | ABL1, CDKN1A, MAP3K13 | GRIN2B 797/4885GRIN1 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.